Same mutation, different allele

被引：110

作者：

Aichberger, Karl J. ^{[1
]}

Fleischman, Angela G. ^{[1
]}

Deininger, Michael W. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

BLOOD | 2009年 / 114卷 / 14期

关键词：

MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; JAK2; HAPLOTYPE; NEOPLASMS; RISK;

D O I：

10.1182/blood-2009-07-229906

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2853 / 2854

页数：2

共 14 条

[1] Mechanisms of disease: The myeloproliferative disorders [J].

Campbell, Peter J. ;

Green, Anthony R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2452-2466

[2] Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation [J].

Campbell, Peter J. ;

Baxter, E. Joanna ;

Beer, Philip A. ;

Scott, Linda M. ;

Bench, Anthony J. ;

Huntly, Brian J. P. ;

Erber, Wendy N. ;

Kusec, Rajko ;

Larsen, Thomas Stauffer ;

Giraudier, Stephane ;

Le Bousse-Kerdiles, Marie-Caroline ;

Griesshammer, Martin ;

Reilly, John T. ;

Cheung, Betty Y. ;

Harrison, Claire N. ;

Green, Anthony R. .

BLOOD, 2006, 108 (10) :3548-3555

[3] Mutation in TET2 in Myeloid Cancers [J].

Delhommeau, Francois ;

Dupont, Sabrina ;

Della Valle, Veronique ;

James, Chloe ;

Trannoy, Severine ;

Masse, Aline ;

Kosmider, Olivier ;

Le Couedic, Jean-Pierre ;

Robert, Fabienne ;

Alberdi, Antonio ;

Lecluse, Yann ;

Plo, Isabelle ;

Dreyfus, Francois J. ;

Marzac, Christophe ;

Casadevall, Nicole ;

Lacombe, Catherine ;

Romana, Serge P. ;

Dessen, Philippe ;

Soulier, Jean ;

Viguie, Franck ;

Fontenay, Michaela ;

Vainchenker, William ;

Bernard, Olivier A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) :2289-2301

[4] A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications [J].

Harrison, CN ;

Gale, RE ;

Machin, SJ ;

Linch, DC .

BLOOD, 1999, 93 (02) :417-424

[5] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[6] JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms [J].

Jones, Amy V. ;

Chase, Andrew ;

Silver, Richard T. ;

Oscier, David ;

Zoi, Katerina ;

Wang, Y. Lynn ;

Cario, Holger ;

Pahl, Heike L. ;

Collins, Andrew ;

Reiter, Andreas ;

Grand, Francis ;

Cross, Nicholas C. P. .

NATURE GENETICS, 2009, 41 (04) :446-449

[7] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms [J].

Kilpivaara, Outi ;

Mukherjee, Semanti ;

Schram, Alison M. ;

Wadleigh, Martha ;

Mullally, Ann ;

Ebert, Benjamin L. ;

Bass, Adam ;

Marubayashi, Sachie ;

Heguy, Adriana ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Offit, Kenneth ;

Stone, Richard M. ;

Gilliland, D. Gary ;

Klein, Robert J. ;

Levine, Ross L. .

NATURE GENETICS, 2009, 41 (04) :455-459

[8] In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm [J].

Lambert, Jonathan R. ;

Everington, Tamara ;

Linch, David C. ;

Gale, Rosemary E. .

BLOOD, 2009, 114 (14) :3018-3023

[9] The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia [J].

Lambert, Jonathan R. ;

Gale, Rosemary E. ;

Linch, David C. .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (01) :128-130

[10]

Moskaluk CA, 1997, CANCER RES, V57, P2140

← 1 2 →